Addressing Patients who are Unaware they have Demodex Blepharitis

Show Description +

Kristin Barnes, OD, and Neda Shamie, MD, explain how they educate Demodex blepharitis patients who have grown accustomed to their symptoms, reviewing questions to ask and highlighting the importance of imaging. They also discuss how to incorporate the evaluation of Demodex blepharitis into a routine eye exam. Real doctors. Paid testimonials. XDEMVY® for DB is available by prescription only. Results may vary.

Posted: 8/12/2025

Addressing Patients who are Unaware they have Demodex Blepharitis

Kristin Barnes, OD, and Neda Shamie, MD, explain how they educate Demodex blepharitis patients who have grown accustomed to their symptoms, reviewing questions to ask and highlighting the importance of imaging. They also discuss how to incorporate the evaluation of Demodex blepharitis into a routine eye exam. Real doctors. Paid testimonials. XDEMVY® for DB is available by prescription only. Results may vary.

Posted: 8/12/2025

Resources

For XDEMVY access support, contact Tarsus Connect by calling 1-866-846-3092

HIPAA Authorization

View Resource

Enrollment Form for the Patient Assistance Program

View Resource

Sample Letter of Appeal

View Resource

Sample Letter of Medical Necessity

View Resource

Prior Authorization Checklist

View Resource

Pharmacy Fax Rx Form

View Resource

Getting Started Guide

View Resource

About XDEMVY

Demodex blepharitis affects ~58% of eye care patients in the US - that’s approximately 25 million patients.3,4 XDEMVY is designed to effectively and safely target, paralyze, and kill Demodex mites in patients with Demodex blepharitis.1

Visit us online: xdemvyhcp.com

Discover More on DB | Contact Us

Indication and Important Safety Information

SHOW MORE

INDICATIONS AND USAGE

XDEMVY is indicated for the treatment of Demodex blepharitis.


IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Risk of Contamination: Do not allow the tip of the dispensing container to contact the eye, surrounding structures, fingers, or any other surface in order to minimize contamination of the solution. Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions.

Use with Contact Lenses: XDEMVY contains potassium sorbate, which may discolor soft contact lenses. Contact lenses should be removed prior to instillation of XDEMVY and may be reinserted 15 minutes following its administration.

ADVERSE REACTIONS: The most common adverse reaction with XDEMVY was instillation site stinging and burning which was reported in 10% of patients. Other ocular adverse reactions reported in less than 2% of patients were chalazion/hordeolum and punctate keratitis.

Please see full Prescribing Information.

INDICATIONS AND USAGE

XDEMVY is indicated for the treatment of Demodex blepharitis.

Important Safety Information:

WARNINGS AND PRECAUTIONS

Risk of Contamination: Do not allow the tip of the dispensing container to contact the eye, surrounding structures, fingers, or any other surface in order to minimize contamination of the solution. Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions.

Use with Contact Lenses: XDEMVY contains potassium sorbate, which may discolor soft contact lenses. Contact lenses should be removed prior to instillation of XDEMVY and may be reinserted 15 minutes following its administration.

ADVERSE REACTIONS: The most common adverse reaction with XDEMVY was instillation site stinging and burning which was reported in 10% of patients. Other ocular adverse reactions reported in less than 2% of patients were chalazion/hordeolum and punctate keratitis.

Please see full Prescribing Information.

1. XDEMVY [prescribing information]. Tarsus Pharmaceuticals, Inc; 2023.

2. Gao YY, Di Pascuale MA, Li W, et al. High prevalence of Demodex in eyelashes with cylindrical dandruff. Invest Ophthalmol Vis Sci. 2005;46(9):3089-3094.

3. Trattler W, Karpecki P, Rapoport Y, et al. The prevalence of Demodex blepharitis in US eye care clinic patients as determined by collarettes: a pathognomonic sign. Clin Ophthalmol. 2022;16:1153-1164.

4. O’Dell L, Dierker DS, Devries DK, et al. Psychosocial impact of Demodex blepharitis. Clin Ophthalmol. 2022;16:2979-2987.